Among the novel therapeutic strategies explored, the therapeutic administration of recombinant BMP9, the main ligand of BMPR2, has been presented as a potential strategy for enhancing endothelial BMP signaling in PAH (Long et al. 2015). Here, BMPR2 is linked to pulmonary arterial hypertension.